Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the... see more

Current News (NDAQ:GLUE)

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire 1 hour ago

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

GlobeNewswire February 24, 2026

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 23, 2026

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

GlobeNewswire January 8, 2026

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 7, 2026

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

GlobeNewswire January 7, 2026

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

GlobeNewswire January 6, 2026

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

GlobeNewswire December 16, 2025

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

GlobeNewswire December 15, 2025
View More News ››

Opinion & Analysis (NDAQ:GLUE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GLUE)

Using technical analysis for this stock.

After making a head and shoulders formation recently,this stock is signalling a big uptrend for shareholders today anyway,so good luck to...
coolfooldumbguy - September 15, 2025
View more Bullboard ››

Mobix Labs Inc

Mobix Labs Inc

Mobix Labs, Inc. designs, develops, and sells components and systems for advanced wireless and wired connectivity, radio ...
View More »

Podcasts